MGLL and sclerosing cholangitis: In addition, we explored the relevance of our findings in a therapeutic setting, treating Mdr2−/− mice (an established model of PSC developing spontaneous sclerosing cholangitis and biliary fibrosis), with the MGL inhibitor JZL184.